Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 23
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Arrowhead Pharmaceuticals Inc
ARWR
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$58.36
-0.48
-0.82%
Ult. Agg.: Oct 22, 4:00 PM
$58.36
-0.48
-0.82%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Arrowhead Pharma Financials
Arrowhead Pharma (ARWR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.32) by 3.03 percent. This is a 7.94 percent decrease over losses of $(1.26) per share from
Benzinga Newsdesk
PRO
Arrowhead Pharma Q2 EPS $(0.93) Beats $(1.14) Estimate, Sales $73.737M Miss $79.991M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(1.14) by 18.42 percent. This is a 133.82 percent decrease over earnings of $2.75 per share from
Benzinga Newsdesk
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pipeline also advancing with promising data.
Vandana Singh
Arrowhead Pharma Q1 Earnings Summary & Key Takeaways
Benzinga Insights
PRO
Arrowhead Pharma Q1 EPS $0.22 Beats $0.14 Estimate, Sales $264.033M Miss $270.066M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.14 by 59.42 percent. This is a 115.83 percent increase over losses of $(1.39) per share from
Benzinga Newsdesk
Earnings Scheduled For February 5, 2026
Benzinga Insights
